statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	866
DE - Germania	229
SG - Singapore	141
CN - Cina	134
SE - Svezia	74
BR - Brasile	54
UA - Ucraina	47
FR - Francia	44
VN - Vietnam	31
IT - Italia	18
IN - India	17
IE - Irlanda	16
FI - Finlandia	10
ID - Indonesia	10
BD - Bangladesh	9
JP - Giappone	9
GB - Regno Unito	7
MX - Messico	6
PK - Pakistan	6
HK - Hong Kong	5
RU - Federazione Russa	5
AE - Emirati Arabi Uniti	4
BE - Belgio	4
CA - Canada	4
EC - Ecuador	4
IQ - Iraq	4
NL - Olanda	4
TR - Turchia	4
ZA - Sudafrica	4
AR - Argentina	3
AT - Austria	3
KR - Corea	3
BB - Barbados	2
CO - Colombia	2
CZ - Repubblica Ceca	2
ES - Italia	2
ET - Etiopia	2
JO - Giordania	2
MA - Marocco	2
PL - Polonia	2
PY - Paraguay	2
BG - Bulgaria	1
CH - Svizzera	1
CL - Cile	1
CR - Costa Rica	1
DZ - Algeria	1
FJ - Figi	1
HN - Honduras	1
HR - Croazia	1
IL - Israele	1
IR - Iran	1
IS - Islanda	1
JM - Giamaica	1
KE - Kenya	1
LA - Repubblica Popolare Democratica del Laos	1
MR - Mauritania	1
NI - Nicaragua	1
NO - Norvegia	1
PS - Palestinian Territory	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
UY - Uruguay	1
VE - Venezuela	1
Totale	1.820

Nome	#
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature	435
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.	196
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes.	193
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms	185
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms	176
Similarities and differences between therapy-related and elderly acute myeloid leukemia	171
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes	170
PU.1 and CEBPA expression in acute myeloid leukemia.	155
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine	149
Totale	1.830

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	1	0	0	0	0	0	0	0	0	0	0	0	1
2021/2022	73	17	10	1	2	5	2	1	13	3	3	8	8
2022/2023	193	18	28	19	37	12	27	9	15	21	1	4	2
2023/2024	80	5	19	4	1	6	22	2	0	0	0	14	7
2024/2025	418	4	4	13	6	16	2	3	14	33	14	287	22
2025/2026	475	76	13	23	40	72	44	73	23	40	45	18	8
Totale													1.830

IRIS UniCatt